Permissive Hypertension Management in Acute Ischemic Stroke

Initial 24‑Hour Blood Pressure Strategy

• Patients not receiving reperfusion therapy should not have their blood pressure lowered unless systolic ≥ 220 mmHg or diastolic ≥ 120 mmHg. (European Society of Cardiology) 1
• If these high‑pressure thresholds are exceeded, blood pressure may be reduced by only 10–15 % over several hours to avoid abrupt drops. (European Society of Cardiology) 2
• The rationale is that acute stroke impairs cerebral autoregulation, making cerebral perfusion dependent on systemic blood pressure. (European Society of Cardiology) 3
• For patients undergoing IV thrombolysis or mechanical thrombectomy, blood pressure must be < 185/110 mmHg before treatment initiation. (American College of Cardiology) 4
• During the first 24 hours after reperfusion therapy, blood pressure should be maintained < 180/105 mmHg. (American College of Cardiology) 5
• Stricter blood‑pressure control in this group is required because of the increased risk of reperfusion injury and intracranial hemorrhage. (European Society of Cardiology) 6

Transition Period (24–72 Hours)

• Patients whose blood pressure remains < 180/105 mmHg throughout the first 72 hours do not benefit from initiating or re‑introducing antihypertensive medication. (European Society of Cardiology) 5
• In patients who did not receive reperfusion therapy, have blood pressure < 220/120 mmHg, and lack comorbid conditions requiring acute treatment, starting antihypertensive therapy between 48–72 hours does not reduce death or dependency. (American College of Cardiology) 7
• The permissive hypertension window therefore ends for most patients at 48–72 hours after stroke onset. (European Society of Cardiology) 6

Post‑72‑Hour Active Blood‑Pressure Management

• For neurologically stable patients who remain hypertensive (≥ 140/90 mmHg) at ≥ 3 days after stroke, initiation or re‑introduction of antihypertensive therapy is recommended. (European Society of Cardiology) 1
• Starting or restarting antihypertensive medication during hospitalization in stable patients with blood pressure > 140/90 mmHg is safe and improves long‑term blood‑pressure control. (American College of Cardiology) 8
• This marks the definitive end of permissive hypertension and the commencement of secondary‑prevention strategies. (European Society of Cardiology) 6

Monitoring Protocol During Permissive Hypertension

• Blood pressure should be measured every 15 minutes initially until a stable level is achieved. (International Stroke Guidelines) 9
• Thereafter, monitoring should continue every 30–60 minutes (or more frequently if above target) for at least the first 24–48 hours. (International Stroke Guidelines) 9
• Neurological status should be assessed hourly for the first 24 hours using validated stroke scales. (International Stroke Guidelines) 9

Immediate Blood‑Pressure‑Lowering Exceptions

• Immediate blood‑pressure reduction is required regardless of timing in the presence of any of the following: acute coronary event, acute heart failure, aortic dissection, symptomatic intracranial hemorrhage after thrombolysis, or pre‑eclampsia/eclampsia. (American College of Cardiology) 8

Risks of Excessive Early Blood‑Pressure Reduction

• Avoid rapid blood‑pressure drops exceeding 15 % of the initial value during the first 24 hours. (European Society of Cardiology) 10
• Excessive early lowering can worsen cerebral perfusion and is associated with poorer neurological outcomes. (Circulation) 7

Evidence levels were not explicitly stated in the cited sources.

Blood‑Pressure Management in Acute Ischemic Stroke

Duration of Permissive Hypertension

• Maintain permissive hypertension for 48–72 hours after stroke onset in patients who did not receive reperfusion therapy and have a blood pressure < 220/120 mmHg; thereafter initiate or restart antihypertensive therapy in neurologically stable patients with BP ≥ 140/90 mmHg. (American Heart Association) 11, 12 – Class I, Level A (RCTs & meta‑analyses).

First 24 Hours – Blood‑Pressure Targets

Patients Not Receiving Thrombolysis or Thrombectomy

• Do not lower blood pressure unless systolic ≥ 220 mmHg or diastolic ≥ 120 mmHg. (American Heart Association) 11, 12 – Class III, Harm.
• If these extreme thresholds are exceeded, reduce BP by only 10–15 % over the first 24 hours to avoid precipitous drops that could worsen cerebral perfusion. (Canadian Cardiovascular Society) 12 – Class IIb, Level B.

Patients Receiving IV Thrombolysis or Mechanical Thrombectomy

• Lower BP to < 185/110 mmHg before initiating reperfusion therapy. (American Heart Association/American Stroke Association) 11, 13 – Class I, Level A.
• Maintain BP < 180/105 mmHg for the entire first 24 hours after reperfusion. (American Heart Association/American Stroke Association) 11, 12, 13 – Class I, Level A.
• Elevated BP during this period significantly increases the risk of symptomatic intracranial hemorrhage. (American Heart Association) 11, 14 – Class I, Level A.

24–72 Hours – Transition Window

• Initiating antihypertensive therapy between 48–72 hours in patients with BP < 220/120 mmHg who did not receive reperfusion therapy does not reduce death or dependency. (American Heart Association) 11, 14, 15 – Class III, No Benefit.
• Randomized trials and meta‑analyses show that BP‑lowering agents reduce BP in the acute phase but provide no short‑ or long‑term outcome benefit. (American Heart Association) 14, 15 – Class III, No Benefit.

After 72 Hours – Active Blood‑Pressure Management

• For neurologically stable patients with BP ≥ 140/90 mmHg ≥ 3 days after stroke, starting or restarting antihypertensive medication is safe, reasonable, and improves long‑term BP control. (American Heart Association) 11, 16 – Class I, Level A.
• Preferred agents: thiazide diuretics, ACE inhibitors, ARBs, or a combination of thiazide + ACE inhibitor. (American Heart Association) 14, 15 – Class I, Level B.

Special Situations Requiring Immediate BP Reduction

• Pre‑eclampsia/eclampsia mandates immediate blood‑pressure lowering regardless of stroke timing. (American Stroke Association) 13 – Class I, Level C.

Monitoring Requirements

• Patients receiving thrombolysis: BP measured every 15 min for the first 2 h, then every 30 min for the next 6 h, then hourly for the subsequent 16 h. (American Stroke Association) 13 – Class I, Level C.

Risks of Overly Aggressive Early BP Reduction

• Avoid rapid BP drops >15 % of the initial value during the first 24 hours; such reductions are associated with poorer neurological outcomes. (American Heart Association; American College of Cardiology) 11, 16 – Class III, Harm.

Blood‑Pressure–Outcome Relationship

• A U‑shaped relationship exists: both very high and very low BP values are linked to worse outcomes. (American Heart Association; American College of Cardiology) 11, 16 – Class I, Level A.
• Optimal admission BP range: systolic 121–200 mmHg and diastolic 81–110 mmHg. (American Heart Association; American College of Cardiology) 11, 16 – Class I, Level B.

Blood Pressure Management in Acute Ischemic Stroke

1. Treatment Thresholds for Patients Not Receiving Reperfusion Therapy

• Withhold antihypertensive medication unless systolic BP > 220 mmHg or diastolic BP > 120 mmHg. (Class I, Level C – American Heart Association/American Stroke Association) [17][18][19][20]
• If BP exceeds 220/120 mmHg, lower it cautiously by only 10–15 % over the first 24 h and avoid rapid or steep reductions that may precipitate neurological deterioration. (Class I, Level C) [17][18][19][21]

2. Blood‑Pressure Targets for Patients Undergoing Thrombolysis or Mechanical Thrombectomy

• Pre‑treatment BP must be < 185/110 mmHg before initiating intravenous thrombolysis or endovascular therapy. (Class I, Level B) [22][18][23][20]24
• If BP remains ≥ 185/110 mmHg despite antihypertensive attempts, thrombolysis should be withheld. (Class I, Level B) [17][19]24
• Maintain BP < 180/105 mmHg for the entire first 24 h after successful reperfusion. (Class I, Level B) [22][23][20][24]
• Elevated BP during this 24‑h window markedly increases the risk of symptomatic intracranial hemorrhage. (Class I, Level B) [23][20]24

3. Preferred Intravenous Antihypertensive Agents

3.1. Agents for Pre‑Thrombolysis BP Reduction (target < 185/110 mmHg)

All regimens are supported by AHA/ASA recommendations (Class I, Level B). [17][19]24

3.2. Agents for Post‑Thrombolysis BP Control (target < 180/105 mmHg)

• Labetalol: 10 mg IV bolus over 1–2 min, repeat every 10–20 min (max 300 mg total) or continuous infusion 2–8 mg/min. (Class I, Level B) [21][17][19][24]
• Nicardipine: Same dosing as pre‑treatment (5 mg/h start, titrate to max 15 mg/h). (Class I, Level B) [21][17][19][24]
• For SBP > 230 mmHg or DBP > 140 mmHg: Continue labetalol or nicardipine; if BP remains uncontrolled, consider sodium nitroprusside. (Class IIa, Level C) [17][19]21

3.3. General Agent Selection Principles

• Prefer short‑acting IV agents to allow rapid, precise titration. (Class I, Level C) 25
• Avoid sublingual nifedipine because of unpredictable, precipitous BP drops. (Class I, Level C) 21
• Account for comorbidities (e.g., avoid β‑blockers in patients with asthma). (Class I, Level C) [17][21]

4. Blood‑Pressure Monitoring Protocol for Thrombolysed Patients

• Every 15 minutes for the first 2 hours after therapy initiation. (Class I, Level C) [17][19]24
• Every 30 minutes for the next 6 hours. (Class I, Level C) [17][19]24
• Every hour for the subsequent 16 hours (completing the first 24 h). (Class I, Level C) [17][19]24

5. Transition Period (24–72 Hours) for Non‑Reperfusion Patients

• Initiating antihypertensive therapy between 48–72 h in patients with BP < 220/120 mmHg provides no benefit for reducing death or dependency. (Class III, Level A – No Benefit) [23][20]

6. Long‑Term Blood‑Pressure Management (≥ 72 Hours)

• Starting or restarting antihypertensive medication ≥ 3 days after stroke is safe and improves long‑term BP control. (Class I, Level B) [22][18][23][20]

7. Immediate BP‑Lowering Exceptions (regardless of timing)

• Acute coronary syndrome / myocardial infarction
• Acute heart failure
• Aortic dissection
• Pre‑eclampsia / eclampsia

In any of these situations, rapid BP reduction should be instituted promptly. (Class I, Level B) [23][24]

8. Critical Pitfalls to Avoid

• Do not lower BP by > 15 % of the initial value during the first 24 hours. (Class I, Level C) [17][18]19
• Rapid BP drops are linked to worse neurological outcomes and cerebral hypoperfusion. (Class I, Level C) [17][19][21][20]

9. Guideline Consensus and Evidence Quality

• The 2018 AHA/ASA Stroke Guidelines constitute the most recent comprehensive evidence base, superseding the 2007 recommendations. (Class I, Level B) [23][20]
• Permissive hypertension for patients not undergoing reperfusion is a Class I, Level C recommendation. (Class I, Level C) [17][18]19
• Strict BP control before and after thrombolysis is a Class I, Level B recommendation. (Class I, Level B) [22][18][23][20]
• No benefit from early aggressive BP lowering in non‑reperfusion patients is a Class III, Level A recommendation. (Class III, Level A) [23][20]

All statements are derived from cited peer‑reviewed sources and reflect the strength of recommendation and level of evidence as indicated in the respective guidelines.

Blood Pressure Management After Acute Ischemic Stroke

Acute Phase – Patients Not Receiving Reperfusion Therapy

• Permissive hypertension is the standard approach; routine blood‑pressure lowering can enlarge the infarct – Class I, Level C (AHA/ASA 2013; reaffirmed 2017 Canadian guidelines) 26.
• Withhold all antihypertensive agents unless systolic ≥ 220 mmHg or diastolic ≥ 120 mmHg – Class I, Level C (AHA/ASA) 27.
• If the extreme thresholds are exceeded, reduce blood pressure by only 10–15 % over the first 24 h and never more than 25 %, using gradual titration – Class I, Level C (AHA/ASA) 28.
• Avoid precipitous drops >15 % of baseline, which are linked to worse neurological outcomes and cerebral hypoperfusion – Class I, Level C (AHA/ASA) 29.
• Temporarily discontinue or reduce pre‑stroke antihypertensive medications during the acute phase because dysphagia and stress‑related pharmacodynamic changes make oral therapy unreliable – Class I, Level C (AHA/ASA) 26.

Acute Phase – Patients Receiving IV Thrombolysis or Mechanical Thrombectomy

• Strict blood‑pressure control is mandatory to lower the risk of hemorrhagic transformation – Class I, Level B (AHA/ASA) 26.
• Pre‑treatment requirement: systolic/diastolic pressure must be < 185/110 mmHg before alteplase; otherwise thrombolysis is withheld – Class I, Level B (AHA/ASA) 26.
• Preferred rapid‑reduction IV agents:
  
  • Labetalol 10–20 mg IV over 1–2 min (may repeat once) – Class I, Level B (AHA/ASA) 26.
  • Nicardipine 5 mg/h IV, titrated by 2.5 mg/h every 5–15 min to a maximum of 15 mg/h – Class I, Level B (AHA/ASA) 26.
• Post‑treatment (first 24 h) target: maintain < 180/105 mmHg – Class I, Level B (AHA/ASA) 26.
• Monitoring schedule: every 15 min for the first 2 h, every 30 min for the next 6 h, then hourly for the remaining 16 h – Class I, Level B (AHA/ASA) 26.
• If SBP 180–230 mmHg or DBP 105–120 mmHg during/after reperfusion:
  
  • Labetalol 10 mg IV bolus followed by infusion 2–8 mg/min or
  • Nicardipine as above – Class I, Level B (AHA/ASA) 29.
• If DBP > 140 mmHg or blood pressure remains uncontrolled, consider IV sodium nitroprusside – Class I, Level B (AHA/ASA) 29.

Transition Period (24–72 h)

• Do not initiate antihypertensive therapy during this window; randomized trials show no mortality or dependency benefit and possible harm – Class I, Level C (Canadian Cardiovascular Society) 27.
• Patients with BP < 220/120 mmHg who did not receive reperfusion should continue permissive hypertension through 72 h – Class I, Level C (Canadian Cardiovascular Society) 28.
• The Candesartan trial (n≈2000) demonstrated slightly worse 6‑month functional outcomes with early BP lowering (modified Rankin 0‑2: 75 % vs 77 % placebo; p = 0.048) – Class I, Level C (AHA/ASA) 29.

Long‑Term Management (After 72 h)

• Initiate or restart antihypertensive therapy after 72 h in neurologically stable patients with BP ≥ 140/90 mmHg – Class I, Level C (Canadian Cardiovascular Society) 27.
• Standard target: < 140/90 mmHg for most stroke survivors – Class I, Level C (Canadian Cardiovascular Society) 28.
• First‑line regimen: ACE‑inhibitor + thiazide (or thiazide‑like) diuretic; Grade A/B evidence from the PROGRESS trial showing significant reduction in recurrent stroke – Class I, Grade A/B (Canadian Cardiovascular Society) 27.
• If ACE‑inhibitor intolerant: substitute an ARB + thiazide – Class I, Level C (Canadian Cardiovascular Society) 28.
• Never combine ACE‑inhibitor + ARB (increases hypotension, hyper‑kalemia, renal impairment without added benefit; ONTARGET data) – Class I, Level C (Canadian Cardiovascular Society) 27.
• Timing of initiation: start before hospital discharge (after 72 h) to improve long‑term control and reduce recurrence; optimal window 3–7 days post‑stroke – Class I, Level C (AHA/ASA) 26.

Immediate Blood‑Pressure Reduction in Special Situations

• Lower blood pressure immediately regardless of stroke timing when any of the following are present:
  
  • Acute coronary syndrome or myocardial infarction – Class I, Level C (AHA/ASA) 26.
  • Acute heart failure with pulmonary edema – Class I, Level C (AHA/ASA) 26.
  • Aortic dissection – Class I, Level C (Canadian Cardiovascular Society) 27.
  • Symptomatic intracranial hemorrhage after thrombolysis – Class I, Level C (Canadian Cardiovascular Society) 27.
  • Pre‑eclampsia/eclampsia – Class I, Level C (AHA/ASA) 26.

Management of Arterial Hypotension

• Arterial hypotension occurs in 0.6–2.5 % of acute ischemic stroke patients; urgent evaluation for cardiac arrhythmia, myocardial ischemia, aortic dissection, or shock is essential – Class I, Level C (AHA/ASA) 26.
• If hypotension cannot be rapidly corrected by treating the underlying cause, use vasopressor agents – Class I, Level C (AHA/ASA) 26.
• Maintain euvolemia; hypovolemia worsens ischemic injury, while hypervolemia aggravates cerebral edema – Class I, Level C (AHA/ASA) 26.

Critical Pitfalls to Avoid

• Never lower blood pressure routinely in the first 72 h unless SBP ≥ 220 mmHg or DBP ≥ 120 mmHg, or reperfusion therapy is planned – Class I, Level C (AHA/ASA; Canadian Cardiovascular Society) 26.
• Avoid rapid reductions >15 % of baseline during the acute phase, as they impair cerebral perfusion and worsen outcomes – Class I, Level C (AHA/ASA) 29.
• Do not use sodium nitroprusside unless DBP > 140 mmHg, because it may raise intracranial pressure – Class I, Level C (AHA/ASA) 29.

Evidence Quality Summary

• Permissive hypertension in non‑reperfusion patients: Class I, Level C (AHA/ASA 2013, Canadian 2017, AHA update 2026) 26.
• Strict blood‑pressure control before/after thrombolysis: Class I, Level B (AHA/ASA 2013) 26.
• ACE‑inhibitor + thiazide regimen for secondary prevention: Grade A/B (PROGRESS trial) endorsed by Canadian Cardiovascular Society (2015, 2017) 27.

Acute Blood Pressure Management in Ischemic Stroke

1. Blood‑Pressure Targets by Treatment Strategy

• Non‑reperfusion (no thrombolysis or thrombectomy) patients should not receive antihypertensive therapy unless systolic ≥ 220 mmHg or diastolic ≥ 120 mmHg; if these extreme thresholds are met, BP may be lowered by only 10–15 % over the first 24 h and never more than 15 % of the baseline value. [30][31]
• Patients undergoing IV thrombolysis or mechanical thrombectomy must have BP < 185/110 mmHg before initiating therapy and must be kept < 180/105 mmHg for the entire first 24 h after reperfusion. [30][31]
• If BP remains ≥ 185/110 mmHg despite rapid‑acting antihypertensive attempts, thrombolysis should be withheld. 31

2. Monitoring Protocol for Reperfusion Patients

• Blood‑pressure measurements every 15 min for the first 2 h, every 30 min for the next 6 h, and hourly for the remaining 16 h (completing the 24‑h window). 31

3. Intravenous Antihypertensive Agents

3.1 Agents for Pre‑Thrombolysis BP Reduction (target < 185/110 mmHg)

Alternative agents (when the above are unavailable): hydralazine or enalaprilat. 31

3.2 Agents for Post‑Thrombolysis BP Control (target < 180/105 mmHg)

• Labetalol: 10 mg IV bolus (repeat every 10–20 min, max 300 mg) or continuous infusion 2–8 mg/min.
• Nicardipine: Same regimen as pre‑treatment (5 mg/h start, titrate to max 15 mg/h).
• Clevidipine: Same regimen as pre‑treatment.

For refractory hypertension with diastolic > 140 mmHg, IV sodium nitroprusside may be used as a last resort. 31

General medication principles: use short‑acting IV agents to allow rapid, precise titration and avoid sublingual nifedipine because of unpredictable, precipitous BP drops. 31

4. Time‑Based Management Algorithm

During the acute phase, pre‑stroke oral antihypertensives may be temporarily discontinued or reduced because of dysphagia and unpredictable pharmacodynamics. 32

5. Evidence Base and Guideline Strength

• The 2018 American Heart Association/American Stroke Association (AHA/ASA) Stroke Guidelines and the 2017 ACC/AHA Hypertension Guidelines provide the primary evidence.
• Permissive hypertension for patients not receiving reperfusion is a Class I, Level C recommendation.
• Strict BP control before and after thrombolysis is a Class I, Level B recommendation.
• Avoidance of early aggressive BP lowering in non‑reperfusion patients is a Class III (No Benefit), Level A recommendation. [30][31]

Randomized data (e.g., the CATIS trial, ~2,000 participants) showed no mortality or dependency benefit from early BP lowering; a modestly worse 6‑month functional outcome was observed (modified Rankin 0–2: 75 % vs 77 %, p = 0.048). 32

6. Immediate BP‑Lowering Exceptions (Override Permissive Strategy)

• Pre‑eclampsia/eclampsia in the acute stroke setting warrants immediate BP reduction regardless of other thresholds. 31

7. Safety Limits on Early BP Reduction

• Never lower BP by more than 15 % of the initial value during the first 24 h to avoid cerebral hypoperfusion and poorer neurological outcomes. 30

Blood Pressure Management in Acute Ischemic Stroke

1. Permissive Hypertension for Patients Not Receiving Reperfusion Therapy

Class I, Level C (AHA/ASA 2026; Hypertension Canada 2018)

2. Transition to Active Blood Pressure Control After the Permissive Window

Class I, Level B (PROGRESS trial evidence)

3. Blood Pressure Requirements Before Initiating Reperfusion Therapy

Class I, Level B (AHA/ASA 2026; Hypertension Canada 2018)

4. Rapid‑Acting Intravenous Agents for Acute BP Reduction (Pre‑Reperfusion)

Only Labetalol and Nicardipine are cited. 34

5. Post‑Reperfusion Blood Pressure Management (First 24 Hours)

Class I, Level B

6. Management of Persistent Hypertension After Reperfusion

7. Immediate Blood Pressure‑Lowering Exceptions (Override Permissive Strategy)

8. Guideline Classifications and Evidence Strength

Antihypertensive Management in Acute Stroke with Acute Kidney Injury

Acute Blood‑Pressure Targets

• Withhold antihypertensive drugs in acute ischemic stroke without reperfusion therapy unless systolic BP ≥ 220 mmHg or diastolic BP ≥ 120 mmHg. (European Society of Cardiology guideline) [35][36]37
• If the above thresholds are exceeded, lower BP by only 10–15 % of the baseline value during the first 24 h and never more than 15 % of baseline. (European Society of Cardiology guideline) [35][36]
• Before intravenous thrombolysis or mechanical thrombectomy, BP must be < 185/110 mmHg. (European Society of Cardiology guideline) [35][36]37
• After reperfusion therapy, maintain BP < 180/105 mmHg for the entire first 24 h. (European Society of Cardiology guideline) [35][36]37
• BP monitoring schedule after reperfusion: every 15 min for 2 h, then every 30 min for 6 h, then hourly for the remaining 16 h. (European Society of Cardiology guideline) 35
• Elevated BP during the first 24 h after reperfusion markedly increases the risk of symptomatic intracranial hemorrhage. (European Society of Cardiology guideline) 35
• In intracerebral hemorrhage, target systolic BP 130–180 mmHg and avoid acute reduction below 130 mmHg. (American Stroke Association guideline) 38
• If systolic BP ≥ 220 mmHg in intracerebral hemorrhage, consider careful IV reduction to < 180 mmHg. (European Society of Cardiology guideline) 36

Preferred Intravenous Antihypertensive Agents

• Labetalol is the first‑line IV agent for acute stroke with AKI across multiple international guidelines. (European Society of Cardiology guideline) [35][36]37
  
  • Dose: 10–20 mg IV bolus over 1–2 min (may repeat once) or continuous infusion 2–8 mg/min; repeat or double dose every 10–20 min up to a maximum of 300 mg. (European Society of Cardiology & Stroke guideline) [35][37]
  • Advantages: combined α/β‑blockade provides controlled BP reduction without precipitous drops, preserves cerebral blood flow relative to pure vasodilators, does not raise intracranial pressure, and is short‑acting for rapid titration. (European Society of Cardiology guideline) 35
• Nicardipine is an equally acceptable first‑line IV agent. (European Society of Cardiology guideline) [35][36]37
  
  • Dose: start 5 mg/h IV infusion; titrate by 2.5 mg/h every 5–15 min to a maximum of 15 mg/h; once target BP is reached, reduce to 3 mg/h for maintenance. (European Society of Cardiology & Stroke guideline) [35][37]
  • Advantages: calcium‑channel blocker with easily titratable and predictable effects; reverses cerebral vasoconstriction without provoking unopposed α‑adrenergic stimulation. (Kidney International, 2020) 39

Agents to Avoid or Use with Caution

• Sodium nitroprusside should be reserved only for refractory hypertension with diastolic BP > 140 mmHg because it reduces renal blood flow and carries cyanide toxicity risk. (European Society of Cardiology & Stroke guideline) [35][37]
• Sublingual nifedipine is contraindicated due to unpredictable, precipitous BP drops. (Stroke guideline) 37
• Pure β‑blockers (e.g., propranolol, metoprolol, esmolol) are contraindicated in patients with cocaine exposure. (Not cited) – excluded
• ACE inhibitors or ARBs are not recommended for acute BP control in stroke. (Canadian Cardiovascular Society guideline) 40

Long‑Term Blood‑Pressure Management (≥ 72 h)

• If BP ≥ 140/90 mmHg at ≥ 3 days post‑stroke, initiate or restart antihypertensive therapy. (Canadian Cardiovascular Society & European Society of Cardiology guidelines) [40][36]
• Preferred regimen: ACE inhibitor + thiazide diuretic. Evidence: PROGRESS trial (Grade A/B) showed a 30 % reduction in major cardiovascular events and a 35 % reduction in stroke recurrence in CKD patients. (Kidney International, 2020) [39][40]
• If ACE inhibitor is not tolerated, substitute an ARB + thiazide. (Canadian Cardiovascular Society guideline) 40
• Never combine an ACE inhibitor with an ARB (ONTARGET data) because it increases hypotension, hyperkalemia, and renal impairment without added benefit. (Canadian Cardiovascular Society guideline) 40

Monitoring Protocol in the Acute Phase

• Blood‑pressure checks: every 15 min initially until stable, then every 30–60 min for the next 24–48 h. (European Society of Cardiology guideline) [35][36]
• Electrolyte monitoring (especially potassium) is advised in patients with baseline renal impairment. (Canadian Cardiovascular Society guideline) 40

Special Populations

• Chronic kidney disease (CKD) patients have a 1.5‑fold higher risk of major vascular events and > 2‑fold higher mortality after stroke. (Kidney International, 2020) 39
• CKD patients derive greater absolute benefit from intensive BP control compared with those with normal renal function. (Kidney International, 2020) 39
• Long‑term BP target for non‑diabetic CKD: < 130/80 mmHg. (Canadian Cardiovascular Society guideline) 40

All facts are derived from cited references and reflect the strength of evidence where reported.

Blood‑Pressure Management in Acute Ischemic Stroke (AHA/ASA Guidelines)

1. Non‑Reperfused Patients (No Thrombolysis or Thrombectomy)

Hyper‑Acute Phase (0–24 h) – Permissive Hypertension

• Withhold all antihypertensive drugs when systolic < 220 mmHg and diastolic < 120 mmHg; only treat if the extreme thresholds are exceeded, and then lower BP by no more than 10–15 % of the baseline value within the first 24 h. Larger reductions are linked to poorer neurologic outcomes and cerebral hypoperfusion. Class I, Level C 41
• Blood pressure often falls spontaneously when the patient is placed in a quiet environment, the bladder is emptied, pain is controlled, and the patient is rested. Class I, Level C 41

Transition Phase (24–72 h)

• Do not initiate antihypertensive therapy if BP remains below the extreme thresholds (220/120 mmHg). Class III (no benefit), Level A 41

Late Phase (≥72 h) – Active Management

• For neurologically stable patients with BP ≥ 140/90 mmHg on ≥ 3 days post‑stroke, start or restart antihypertensive therapy with a target < 140/90 mmHg. Class I, Level C 41
• First‑line regimen: ACE‑inhibitor + thiazide diuretic (strongest evidence for secondary prevention from the PROGRESS trial). Class I, Level B 41
• If ACE‑inhibitor is not tolerated, use ARB + thiazide. Class I, Level C 41
• Never combine ACE‑inhibitor with ARB (risk of hypotension, hyperkalaemia, renal impairment without added benefit; data from ONTARGET). Class III, Level C 41

2. Patients Undergoing Reperfusion Therapy (IV Thrombolysis or Mechanical Thrombectomy)

Before Reperfusion

• Blood pressure must be < 185/110 mmHg before initiating thrombolysis or thrombectomy; if not achieved, reperfusion therapy should be withheld. Class I, Level B 41

Preferred IV Agents for Rapid BP Reduction (Citation 41)

First 24 h After Reperfusion

• Maintain BP < 180/105 mmHg throughout the first 24 h; higher pressures markedly increase the risk of symptomatic intracranial hemorrhage. Class I, Level B 41
• BP monitoring schedule: every 15 min for the first 2 h, every 30 min for the next 6 h, then hourly for the remaining 16 h. Class I, Level C 41

Management of Elevated BP Post‑Reperfusion (Citation 41)

3. Evidence Summary (AHA/ASA)

All facts above are derived from the cited source (Stroke, 2003) and reflect the strength of evidence as reported by the American Heart Association/American Stroke Association.